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More on ‘universal’ versus ‘selected’ screening for
thrombophilia: the hidden costs of false-positive
diagnosis – response to Favaloro and Keeling
We thank Dr Favaloro and Dr Keeling (Keeling, 2006) for their
correspondence.
Dr Favaloro referred to the accuracy of diagnosis of
thrombophilia, in particular inherited deficiencies in protein
C and protein S. The uncertainty about normality and
deficiency for these physiological anticoagulants has been long
recognised (Greaves & Baglin, 2000) and was addressed in our
study.
Our decision model took into account the following patient
pathways: (i) test positives (true positives) – patients with
thrombophilia and accurately tested positive; (ii) false positives
– patients with thrombophilia, but inaccurately tested negative;
(iii) false positives – patients without thrombophilia, but
inaccurately tested positive; and (iv) test negatives (true
negatives) – patients without thrombophilia and accurately
tested negative. Therefore, the false-positive diagnosis was
represented by patient pathway (iii). As in clinical practice,
following a positive-test result, the model assumed that these
patients would be given prophylaxis; however, the probability
of subsequent venous thromboembolic events in these patients
would be lower than those with a true-positive result.
The test sensitivity and specificity for individual tests for
thrombophilia is unclear. Based on the limited existing data in
the literature (Preston et al, 2003) we assumed the overall
sensitivity and specificity of the thrombophilia screening tests
to be 80% in the main analysis. As Dr Favaloro has highlighted,
this may be an overestimate in testing for protein C and
protein S. Therefore, this was tested in the sensitivity analysis,
in which we varied the test sensitivity and specificity between
50% and 100%. This resulted in substantial changes in the
incremental cost-effectiveness ratios, but did not alter the
overall results.
Cost-effectiveness analysis is based on the fundamental
assumption that the comparisons apply to where the decision
maker is already faced with a budget and mutually exclusive
options. Incremental cost-effectiveness ratios are ranked with
the least cost per unit of health effect being the most desirable.
Our study showed that when comparing the high-risk patient
groups, screening prior to prescribing hormone replacement
therapy was the most cost-effective strategy (incremental cost-
effectiveness ratio £6824). However, when comparing universal
screening with selective screening, selective screening was more
cost-effective in all groups.
Dr Keeling referred to scenarios where purchasers express a
willingness to pay £15 000 or £80 000 to achieve a unit of
outcome (Keeling, 2006). We disagree that this would mean
that universal screening for some groups would therefore be
preferred to selective screening. The option with the lowest
cost per unit of outcome in a comparison (such as selective
compared with universal screening) would always be chosen, as
this would free resources to be available for other cost-effective
uses. We believe that cost-effectiveness acceptability thresholds
should be used to compare different healthcare programmes.
Our study was not designed to evaluate the relative cost-
effectiveness of screening compared with other uses of scarce
NHS resources. In order to evaluate this, alternative forms of
economic evaluation, which allow comparisons between
diverse healthcare programmes, such as cost–benefit or cost–
utility analysis (Drummond et al, 1987), are required.
Olivia Wu
Ian Greer on behalf of the Treats Study Group
Division of Developmental Medicine, University of Glasgow, Glasgow,
UK. E-mail: i.a.greer@clinmed.gla.ac.uk
References
Drummond, M.F., Stoddart, G.L. & Torrance, G.W. (1987) Methods
for the Economic Evaluation of Health Care Programmes. Oxford
University Press, Oxford.
Greaves, M. & Baglin, T. (2000) Laboratory testing for heritable
thrombophilia: impact on clinical management of thrombotic dis-
ease. British Journal of Haematology, 109, 699–703.
Keeling, D. (2006) Universal or selected screening for thrombophilia.
British Journal of Haematology, 133, 106–107.
Preston, F.E., Jennings, I., Kitche, S. & Woods, T.A.L. (2003) Accuracy
of laboratory diagnosis of familial thrombophilia, 2001–2002:
UK NEQAS. Journal of Thrombosis and Haemostasis, 1 (abstract
OC326).
Keywords: thrombophilia, laboratory testing, false positives.
For Evaluation Only.
Copyright (c) by Foxit Software Company, 2004 - 2007
Edited by Foxit PDF Editor
